ReviewClinical science (London, England : 1979)2026
Human cytomegalovirus at the maternal-fetal interface: an overview of pathogenesis, defence, and interventions.
Review in Clinical science (London, England : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Human cytomegalovirus (HCMV) is the leading infectious cause of congenital disease worldwide and a major contributor to birth defects and neurodevelopmental disorders. Vertical transmission occurs when the virus breaches the maternal-fetal interface, a complex immunological environment where the placenta is in direct contact with either the uterine lining (decidua) or maternal blood covering the syncytium. The present review synthesises current understanding of HCMV pathogenesis at this critical interface, examining viral invasion mechanisms, host immune responses, and immune evasion strategies. We outline the structural and cellular features of the placenta and decidua, highlighting key immune populations such as uterine natural killer cells and their roles in antiviral defence. The present review examines the mechanisms of HCMV dissemination across the placenta alongside placental-specific defences to infection and details on how HCMV subverts both innate and adaptive immunity to establish and maintain infection. Critical gaps in diagnostics, the limited efficacy of current antiviral therapies, and obstacles in vaccine development are reviewed, underscoring the urgent need for prevention strategies. Finally, we assess experimental models, placental explants, primary trophoblast and decidual organoids, and microfluidic placenta-on-chip systems that are advancing insights into cell-type-specific tropism, immune interactions, and mechanisms of transplacental HCMV transmission. Continued research into host-virus interactions at the maternal-fetal interface and improved model systems are critical for developing targeted prevention and treatment strategies to reduce the burden of congenital HCMV infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.